Mirum says Phase 3 AZURE-1 trial meets primary endpoint for brelovitug in chronic hepatitis delta
Mirum said Week 24 results in chronic hepatitis delta showed improved viral control and liver inflammation versus delayed treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Mirum Pharmaceuticals says Phase 3 AZURE-1 met primary endpoint in chronic HDV study
The company said brelovitug met the Phase 3 primary endpoint at Week 24 in both dose arms. Mirum also reported 48-week Phase 2b data showing deeper viral suppression and no new safety signals.
Mirum Pharmaceuticals says Phase 3 AZURE-1 met primary endpoint
Mirum Pharmaceuticals said its Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus met its primary endpoint.